What if the neuropathy in front of you isn’t what it seems? Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common immune-mediated peripheral neuropathy, yet it remains widely underrecognized. Because its symptoms mimic other neuropathies, CIDP is too often misdiagnosed …
Generalized myasthenia gravis (gMG) is a chronic autoimmune neuromuscular disease that can profoundly disrupt strength and independence through unpredictable, fluctuating muscle weakness. Recent advances have transformed the treatment landscape, with targeted therapies such as neonatal Fc receptor (FcRn) inhibitors and …
The obesity pipeline is moving faster than the evidence can be absorbed. A new class of amylin-based agents — investigational therapies now advancing through phase 2 and phase 3 trials with several studied both on their own and in combination …
Obesity looks like one diagnosis but behaves like many. Two patients with the same body mass index (BMI) can respond very differently to the same medication, and as the treatment armamentarium expands, from today’s incretins to the amylin-based and combination …
The treatment landscape for locally advanced head and neck squamous cell carcinoma (LA HNSCC) has historically been anchored by surgery, radiation therapy, and chemoradiation. Care for this complex disease requires navigating diverse tumor biology, multiple sites of origin, and significant …
Obesity care is moving quickly past the one-drug, one-pathway era. Current therapies have reshaped what treatment can achieve, yet responses vary widely and not every patient tolerates or responds to them, leaving clinicians searching for the next complementary mechanism. Amylin …
More than 40% of U.S. adults now live with obesity, and incretin-based therapies have transformed what treatment can achieve. Yet the same clinical experience that produced those gains has exposed their limits: response varies widely from patient to patient, persistence …
Chronic inflammatory demyelinating polyneuropathy (CIDP) presents ongoing diagnostic and therapeutic challenges due to its clinical heterogeneity, evolving pathophysiology, and inconsistent responses to standard treatment. Many health care professionals, particularly those in neurology-focused settings, require current and ongoing education on recognizing …
Chronic lymphocytic leukemia (CLL) has undergone a remarkable therapeutic transformation with the availability of highly effective targeted therapies. However, molecular testing and the integration of prognostic and predictive biomarkers into treatment decisions remain inconsistent, particularly outside tertiary care centers. Because …